Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

NCT06603142 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

636

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Gout
Hyperuricemia

Interventions

DRUG: Febuxostat 20MG Tablets
DRUG: Febuxostat 20MG Placebo
DRUG: AR882 25MG
DRUG: AR882 12.5MG
DRUG: AR882 25MG Placebo
DRUG: AR882 12.5MG Placebo
DRUG: Febuxostat 40MG Tablets
DRUG: Febuxostat 40MG Placebo

Sponsor

Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd